Oral N-acetylcysteine for Retinitis Pigmentosa (NAC Attack)

Clinical Trial

NCT05537220 Active, Not recruiting

NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa

Phase 3

Interventional

Disease

Disease type

Hereditary retinal disease

Retinitis Pigmentosa

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

11/10/2023

Closing date

31/12/2028

Inclusion criteria :

Exclusion criteria :

Funding

private

Members involved

Others investigators

Dr Katarina Stingl

Representative

Germany

Low Vision Daily Life and Patients Groups (TWG5), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Pr Carel HOYNG

Representative

Netherlands

Genetic Diagnostics (TWG6), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Dr Camiel BOON

Representative

Netherlands

Anterior Segment Rare Eye Diseases (WG4), Genetic Diagnostics (TWG6), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader